PMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

Reuters

06-17

<a href="https://laohu8.com/S/ELAB">PMGC Holdings</a> Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases

PMGC Holdings Inc. Initiates Phase II Collaboration for AI-Driven Therapies NEWPORT BEACH, Calif., June 17, 2025 - PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, has announced the initiation of Phase II of its AI Development Program in collaboration with Yuva Biosciences, Inc. The collaboration aims to leverage YuvaBio's MitoNova™ platform, a mitochondrial science-focused AI tool, to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. The program will involve virtual screening of a diverse library of drug-like small molecules to predict their potential in promoting mitochondrial health. The results of this screening will be analyzed to identify opportunities for biological validation. No results have been presented yet; these will follow the completion of the screening and analysis process.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470020-en) on June 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544569960"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544569960\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2544569960?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 21:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544569960","market":"us","top_or_hot":-1,"title":"PMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Holdings Inc. Initiates Phase II Collaboration for AI-Driven Therapies NEWPORT BEACH, Calif., June 17, 2025 - PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, has announced the initiation of Phase II of its AI Development Program in collaboration with Yuva Biosciences, Inc. The collaboration aims to leverage YuvaBio's MitoNova™ platform, a mitochondrial science-focused AI tool, to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. The program will involve virtual screening of a diverse library of drug-like small molecules to predict their potential in promoting mitochondrial health. The results of this screening will be analyzed to identify opportunities for biological validation. No results have been presented yet; these will follow the completion of the screening and analysis process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470020-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 21:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/ELAB\">PMGC Holdings</a> Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        PMGC Holdings Inc. Initiates Phase II Collaboration for AI-Driven Therapies NEWPORT BEACH, Calif., June 17, 2025 - PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, has announced the initiation of Phase II of its AI Development Program in collaboration with Yuva Biosciences, Inc. The collaboration aims to leverage YuvaBio's MitoNova™ platform, a mitochondrial science-focused AI tool, to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. The program will involve virtual screening of a diverse library of drug-like small molecules to predict their potential in promoting mitochondrial health. The results of this screening will be analyzed to identify opportunities for biological validation. No results have been presented yet; these will follow the completion of the screening and analysis process.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470020-en) on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDLGPzqn:1","article_id":"2544569960","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544569960","pubTimestamp":1750165471,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"PMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases. Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire  on June 17, 2025, and is solely responsible for the information contained therein.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4588":"碎股","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4112":"金融交易所和数据","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","ELAB":"PMGC Holdings","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","NDAQ":"纳斯达克OMX交易所","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4183":"个人用品"},"translate_title":"PMGC Holdings Inc.宣布与Yuva Biosciences开展二期合作，开发针对肥胖和心脏代谢疾病的人工智能疗法","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELAB":0.9,"NDAQ":0.9},"content_text":"PMGC Holdings Inc. Announces Phase II Collaboration with Yuva Biosciences to Develop AI-Powered Therapies for Obesity and Cardiometabolic Diseases\n    \n\n        PMGC Holdings Inc. Initiates Phase II Collaboration for AI-Driven Therapies NEWPORT BEACH, Calif., June 17, 2025 - PMGC Holdings Inc., through its subsidiary Northstrive Biosciences, has announced the initiation of Phase II of its AI Development Program in collaboration with Yuva Biosciences, Inc. The collaboration aims to leverage YuvaBio's MitoNova™ platform, a mitochondrial science-focused AI tool, to identify small molecule candidates that enhance mitochondrial health in obesity and cardiac diseases. The program will involve virtual screening of a diverse library of drug-like small molecules to predict their potential in promoting mitochondrial health. The results of this screening will be analyzed to identify opportunities for biological validation. No results have been presented yet; these will follow the completion of the screening and analysis process.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PMGC Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9470020-en) on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}